Royalty Pharma Stock (NASDAQ:RPRX)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$27.10

52W Range

$25.20 - $31.66

50D Avg

$27.95

200D Avg

$28.21

Market Cap

$12.19B

Avg Vol (3M)

$2.29M

Beta

0.46

Div Yield

$0.84 (3.05%)

RPRX Company Profile


Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

75

IPO Date

Jun 16, 2020

Website

RPRX Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Intangible Royalty Assets$835.00K$37.48M$171.25M
Financial Royalty Assets$2.20B$2.13B$2.07B
Royalty Income, Other$155.97M$74.64M$53.13M

Fiscal year ends in Dec 23 | Currency in USD

RPRX Financial Summary


Dec 23Dec 22Dec 21
Revenue$2.35B$2.24B$2.29B
Operating Income$1.49B$977.50M$1.43B
Net Income$1.13B$42.83M$478.75M
EBITDA$1.49B$983.17M$1.48B
Basic EPS$2.54$0.10$1.15
Diluted EPS$2.53$0.10$1.15

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 08, 24 | 2:14 PM
Q1 24May 09, 24 | 12:00 AM
Q4 23Feb 15, 24 | 1:39 PM

Peer Comparison


TickerCompany
AKROAkero Therapeutics, Inc.
DNAGinkgo Bioworks Holdings, Inc.
ADPTAdaptive Biotechnologies Corporation
VECTVectivBio Holding AG
IKNAIkena Oncology, Inc.
IOVAIovance Biotherapeutics, Inc.
APLSApellis Pharmaceuticals, Inc.
BPMCBlueprint Medicines Corporation
DAWNDay One Biopharmaceuticals, Inc.
RPHMReneo Pharmaceuticals, Inc.
CVACCureVac N.V.
BGNEBeiGene, Ltd.
PRMEPrime Medicine, Inc.
KNTEKinnate Biopharma Inc.
ASNDAscendis Pharma A/S
OCEAOcean Biomedical, Inc.
KRTXKaruna Therapeutics, Inc.
MDGLMadrigal Pharmaceuticals, Inc.
AMLXAmylyx Pharmaceuticals, Inc.